John W. Lehmann

TL;DR: The STOP AF trial demonstrated that cryoballoon ablation is a safe and effective alternative to antiarrhythmic medication for the treatment of patients with symptomatic paroxysmal AF, for whom at least one antiarrHythmic drug has failed, with risks within accepted standards for ablation therapy.

TL;DR: RF energy is significantly more thrombogenic than cryoenergy, with a higher incidence of thrombus formation and largerThrombus volumes, likely reflecting intact tissue ultrastructure with endothelial cell preservation.

TL;DR: In this paper, an elongated catheter with a distal balloon assembly is adapted for endovascular insertion, where a secondary outer balloon surrounds a primary inner balloon, the primary balloon being filled with coolant and acting as the cooling chamber, the secondary balloon being coupled to a vacuum return lumen to serve as a robust leak containment device and thermal insulator around the balloon.

TL;DR: The DBS was significantly more effective than diet and exercise in causing weight loss with a low adverse event profile and accommodation symptoms abated rapidly with support and medication.

TL;DR: ERAF after cryoballoon ablation occurs in ≈50% of patients and is strongly associated with LR, and early reablation for ERAF is associated with excellent long-term freedom from recurrent AF.